在患有PNH和骨髓功能受损的患者中,向Pegcetacoplan的个体治疗目标迈进
Jeff Szer1, Jens Panse2,3, Austin Kulasekararaj4
1Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, VIC 3052, Australia.
International journal of molecular sciences
|August 29, 2024
概括
一种C3抑制剂Pegcetacoplan对患有骨髓功能受损的阳性夜间血红蛋白尿症 (PNH) 患者表现有前途. 这种治疗可以在临床上有意义地改善血红蛋白,LDH和疲劳,即使在具有挑战性的情况下.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 透性夜间血红蛋白尿 (PNH) 是一种罕见的,严重的血液学疾病,其特征是补充介导的血液溶解和生活质量的降低.
- 现有的治疗方法可能无法完全解决PNH并发症,特别是在骨髓功能受损的患者中.
研究的目的:
- 评估新型补充C3抑制剂佩格塞塔科普兰在PNH患者和骨髓功能受损患者的疗效.
- 用传统的正常化和临床上有意义的改善指标来评估血液学和临床反应.
主要方法:
- 从PEGASUS和PRINCE临床试验中对Pegcetacoplan治疗的数据进行了后期分析.
- 以血红蛋白<10 g/dL和绝对中性粒细胞数<1.5 × 10^9细胞/L来定义的骨髓功能受损.
- 根据传统的参数规范化和临床上有意义的改善的新定义来评估结果 (例如,Hb增加≥2g/dL,LDH≤1.5xULN,疲劳得分增加≥5分).
主要成果:
- 在传统的正常化下,血红蛋白在20% (PEGASUS) 和43% (PRINCE) 的正常化;LDH在60%和57%的正常化;疲劳得分分别在40%和29%的正常化.
- 使用临床上有意义的改善标准,佩格西塔科普兰导致40% (PEGASUS) 和71% (PRINCE) 患者的血红蛋白改善.
- 在60% (PEGASUS) 和71% (PRINCE) 的LDH中观察到临床上有意义的改善,在60% (PEGASUS) 和43% (PRINCE) 的疲劳得分中观察到有意义的改善.
结论:
- 佩格塞塔科普兰表明,在骨髓功能受损的PNH患者中,血液学和临床参数的临床上有意义的改善有可能实现.
- 这些发现表明,用佩格西塔科普兰抑制C3是一种可行的治疗选择,即使在这个具有挑战性的患者亚组中,也可以解决关键疾病表现.
更多相关视频
11:37Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
Published on: June 18, 2018
6.6K
08:32CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
Published on: August 9, 2022
3.5K
相关概念视频
Bone Marrow Sampling and Transplants
316
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
316
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Stem Cell Therapy for Tissue Regeneration
4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
